DK3395359T3 - Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose - Google Patents

Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose Download PDF

Info

Publication number
DK3395359T3
DK3395359T3 DK16874923.2T DK16874923T DK3395359T3 DK 3395359 T3 DK3395359 T3 DK 3395359T3 DK 16874923 T DK16874923 T DK 16874923T DK 3395359 T3 DK3395359 T3 DK 3395359T3
Authority
DK
Denmark
Prior art keywords
thrombosis
plasminogen
prevention
treatment
chronic
Prior art date
Application number
DK16874923.2T
Other languages
English (en)
Inventor
Jinan Li
Original Assignee
Talengen Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen Int Ltd filed Critical Talengen Int Ltd
Application granted granted Critical
Publication of DK3395359T3 publication Critical patent/DK3395359T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
DK16874923.2T 2015-12-18 2016-12-16 Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose DK3395359T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015097941 2015-12-18
PCT/CN2016/110448 WO2017101866A1 (zh) 2015-12-18 2016-12-16 一种用于预防或治疗急性及慢性血栓的方法

Publications (1)

Publication Number Publication Date
DK3395359T3 true DK3395359T3 (da) 2024-01-15

Family

ID=59055793

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16874923.2T DK3395359T3 (da) 2015-12-18 2016-12-16 Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose

Country Status (8)

Country Link
US (1) US10864257B2 (da)
EP (1) EP3395359B1 (da)
JP (2) JP2019500422A (da)
CN (2) CN115845037A (da)
CA (1) CA3008185C (da)
DK (1) DK3395359T3 (da)
TW (1) TWI653982B (da)
WO (1) WO2017101866A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6682008B2 (ja) * 2015-12-18 2020-04-15 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病性腎症を予防及び治療するための方法
TWI623321B (zh) 2015-12-18 2018-05-11 Talengen Institute Of Life Sciences Co Ltd Method for preventing and treating cervical erosion
EP3395360A4 (en) 2015-12-18 2019-06-12 Talengen International Limited METHOD FOR PREVENTING OR TREATING DIABETIC RETINOPATHY
US11400142B2 (en) 2015-12-18 2022-08-02 Talengen International Limited Treatment of diabetic nerve injury comprising administering plasminogen
CN108463236A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗放射性和化学性损伤的方法
WO2017101871A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗心血管病的新方法
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
CN110114082A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗脂肪代谢紊乱及其相关病症的方法
CN110121358A (zh) 2016-12-15 2019-08-13 泰伦基国际有限公司 一种预防和治疗肺纤维化的方法
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
CN110139667A (zh) 2016-12-15 2019-08-16 泰伦基国际有限公司 一种使胰高血糖素、胰岛素恢复正常平衡的方法
WO2018233604A1 (zh) 2017-06-19 2018-12-27 泰伦基国际有限公司 一种调控glp-1/glp-1r的方法和药物
CN113597313A (zh) * 2019-01-24 2021-11-02 先觉药业咨询公司 用于治疗和预防微血栓形成的纤溶酶原
CN114642722A (zh) * 2020-12-18 2022-06-21 四川大学华西医院 纤溶酶原用于制备促进血管新生的药物中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62153224A (ja) 1985-12-27 1987-07-08 Green Cross Corp:The プラスミノゲン製剤
AU4661493A (en) 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
DK125693D0 (da) 1993-11-05 1993-11-05 Novo Nordisk As
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
WO2003066842A2 (de) 2002-02-06 2003-08-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen
CN1451746A (zh) * 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
CN101015686B (zh) * 2007-02-06 2010-05-19 中国人民解放军军事医学科学院基础医学研究所 一种溶栓药物增效剂及其制备方法
RU2564131C2 (ru) 2009-07-10 2015-09-27 ТромбоДженикс НВ Варианты плазминогена и плазмина
WO2011139973A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Methods of inhibiting fibrosis using anti-pai-1 antibodies
CN102199587B (zh) * 2011-03-24 2013-06-19 广东药学院 人纤溶酶原功能性突变体及其制备方法和应用
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
JP6682008B2 (ja) * 2015-12-18 2020-04-15 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病性腎症を予防及び治療するための方法
US11400142B2 (en) 2015-12-18 2022-08-02 Talengen International Limited Treatment of diabetic nerve injury comprising administering plasminogen

Also Published As

Publication number Publication date
US20190247472A1 (en) 2019-08-15
CN108472342B (zh) 2022-11-15
WO2017101866A1 (zh) 2017-06-22
EP3395359A4 (en) 2019-06-12
CA3008185C (en) 2024-01-16
EP3395359A1 (en) 2018-10-31
TWI653982B (zh) 2019-03-21
US10864257B2 (en) 2020-12-15
JP2020090541A (ja) 2020-06-11
TW201722468A (zh) 2017-07-01
CN115845037A (zh) 2023-03-28
CA3008185A1 (en) 2017-06-22
JP2019500422A (ja) 2019-01-10
EP3395359B1 (en) 2023-11-01
CN108472342A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
DK3395359T3 (da) Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3368534T3 (da) Valbenazin-ditosylat og polymorfer deraf
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
DK3149019T3 (da) Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
DK3325488T3 (da) Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer
DK3693158T3 (da) Asymmetrisk forarbejdningsfremgangsmåde til krumningsreduktion i laminatstrukturer
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3227675T3 (da) Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3227237T3 (da) Indretning og anvendelse deraf til uv-bearbejdning af fluider
DK3096798T3 (da) Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem
DK3368613T3 (da) Matteringsmiddel og fremgangsmåde til fremstilling deraf
DK3432899T3 (da) Anvendelse af probiotika ved behandling og/eller forebyggelse af psoriasis
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3367852T3 (da) Indretning og fremgangsmåde til behandling af levnedsmidler
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3484585T3 (da) Anvendelse af probiotika ved behandling og/eller forebyggelse af atopisk dermatitis
DK3391902T3 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
DK3362449T3 (da) Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
DK3270909T3 (da) Kombinationer af faste doser omfattende ETC1002 og et eller flere statiner til behandling eller reduktion af kardiovaskulær risiko
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3325618T3 (da) Hidtil ukendte trypsin-isoformer og anvendelse deraf